NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal (Committee B) meeting minutes

 **Minutes:** Confirmed

**Date and time:** Thursday 4 February 2021, 9:00am to 17:01pm

**Location:** via Zoom

## Committee members present:

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Dr Carlo Berti Present for all items
4. Dr Laura Bojke Present for items 1 to 4
5. Mr Mark Chapman Present for all items
6. Dr Mark Glover Present for all items
7. Dr Megan John Present for all items
8. Dr Nicholas Latimer Present for all items
9. Dr Veline L’Esperance Present for items 1 to 4
10. Dr Rhiannon Owen Present for all items
11. Ms Anna Pracz Present for all items
12. Mr Peter Wheatley Price Present for all items
13. Dr Brian Shine (TAC A) Present for items 5 and 6
14. Dr Stephen Smith Present for all items
15. Professor Nicky Welton Present for items 1 to 4
16. Mr Nigel Westwood Present for all items
17. Professor Sarah Wild Present for items
18. Ms Mary Weatherstone Present for item 5 and 6
19. Dr Ed Wilson Present for all items
20. Mr Tony Wootton Present for all items

## NICE staff present:

Nicole Elliott, Associate Director Present for items 1 to 4

Ross Dent, Associate Director Present for items 5 and 6

Jeremy Powell, Project Manager Present for all items

Shonagh D’Sylva, Project Manager Present for all items

Ewa Rupniewska, Technical Advisor Present for items 1 to 4

Hannah Nicholas, Technical Analyst Present for items 1 to 4

Richard Diaz, Technical Advisor Present for items 5 and 6

Victoria Gillis-Elliott, Technical Analyst Present for items 5 and 6

Heidi Livingstone, Public Involvement Advisor Present for items 1 to 4.1 and item 5.1

Catherine Pank, Assistant Project Manager Present for items 1 to 4

Mira Patel, Coordinator Present for all items

Gemma Smith, Coordinator Present for all items

Rosalee Mason, Coordinator Present for items 1 to 4.1 and item 5.1

Lucinda Evans, Coordinator Present for items 1 to 4.1 and item 5.1

Daniel Greenwood, Assistant Administrator Present for items 1 to 4.1 and items 5 and 6

## External group representatives present:

Aileen Clarke, Professor of Public Health & Present for items 1 to 4.2

 Health Services Research, Warwick Evidence

Ewen Cummins, Health Economist, Warwick Evidence Present for items 1 to 4.2

Mubarak Patel, Research Associate, Warwick Evidence Present for items 1 to 4.2

Peter Auguste, Research Fellow, Warwick Evidence Present for items 5.1 and 5.2

Amy Grove, Associate Professor, Warwick Evidence Present for items 5.1 and 5.2

## Professional experts present:

Professor Peter Clark, CDF Clinical Lead, NSHE Present for items 1 to 4

Professor Johann de Bono, clinical expert, Regius Professor Present for items 1 to 4.1

 of Cancer Research and Honorary Consultant, The Institute

 of Cancer Research (ICR) and Royal Marsden NHS Trust,

 nominated by Astra Zeneca

Dr Sree Rodda, clinical expert, Consultant Clinical Present for items 1 to 4.1

 Oncologist Leeds Teaching Hospitals, nominated by

 British Uro-oncology Group

Dr Stephen Allen, patient expert, nominated by Tackle Present for items 1 to 4.1

 Prostate Cancer

Peter Isard, patient expert, nominated by Prostate Cancer UK Present for items 1 to 4.1

Dr Helen Ford, clinical expert, Consultant Neurologist, Present for item 5.1

 Leeds Teaching Hospital, nominated by Association

 of British Neurologists

Dr Eli Silber, clinical expert, Consultant Neurologist, Kings Present for item 5.1

 College Hospital, nominated by Novartis

Emma Meadows, patient expert, nominated by Multiple Present for item 5.1

 Sclerosis Trust

## Observers present:

Rebecca Bouch, Assistant Project Manager, NICE Present for item 5.1.1 to 5.1.3

Emilene Coventry, Senior Medical Editor, NICE Present for items 5 and 6

Emily Eaton-Turner, HTA Adviser, NICE Present for items 1 to 4

Hayley Garnett, Senior Medical Editor, NICE Present for items 1 to 4

Ella Livingstone, Technical Advisor, NICE Present for all items

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Stuart Williams.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on 12 November 2020.

### Appraisal of Olaparib for previously treated hormone-relapsed metastatic prostate cancer [ID1640]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from AstraZeneca.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Mr Peter Wheatley-Price, Committee Member, declared non-financial professional and personal interests as Takeda manufacture leuprorelin acetate (Prostap) which is used earlier in the pathway. It was agreed that this declaration was not considered a conflict of interest and would not prevent Mr Wheatley-Price from participating in this section of the meeting.
* Prior to the meeting, Professor Johann de Bono, clinical expert, declared a direct financial interest as he had received support from AstraZeneca to attend a conference at which he presented olaparib data. During the meeting, Professor de Bono, declared a direct financial interest as he sits on advisory boards for AstraZeneca. Professor de Bono also declared an indirect interest as he led on Phase I, II and III trials for prostate cancer patients (TOPARP), supported by funding provided by Astra Zeneca. Professor de Bono declared a further indirect interest as the Institute of Cancer Research (ICR) has a commercial interest in PARP inhibitors for the treatment of DNA repair defective cancers as they hold a patent. It was agreed that these declarations would not prevent Professor de Bono from providing expert advice to the committee.
* Prior to the meeting, Dr Stephen Allen, patient expert, declared a direct financial interest as he received funding from Janssen to support his attendance a patient-centred meeting in Europe. This did not involve any commercial interests. It was agreed that this declaration would not prevent Dr Allen from providing expert advice to the committee.
	+ 1. No further conflicts were declared for this appraisal.
	1. Part 2a – Closed session (company representatives, professional experts and members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

### Appraisal of Ofatumumab for treating relapsing multiple sclerosis [ID1677]

* 1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Novartis.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dr Nicholas Latimer, Committee Member, declared a direct financial interest as Merck Serono organised an ISPOR webinar in December 2020, on modelling treatment sequences and paid him to present on methods for undertaking such analyses. The presentation was not specific to any Merck Serono treatments or any specific disease areas. It was agreed that this declaration would not prevent Dr Latimer from participating in this section of the meeting.
* Prior to the meeting, Dr Eli Silber, clinical expert, declared an indirect interest as he was a trialist. During the meeting, Dr Silber declared a further indirect interest as his unit received financial support from Novartis. Dr Silber did not directly benefit from this financial support. It was agreed that these declarations would not prevent Dr Silber from providing expert advice to the committee.
* Prior to the meeting, Dr Helen Ford, clinical expert, declared direct financial interests as she received honoraria for advisory boards, speaker fees or support to attend educational meetings from Biogen (22/01/2020) and Novartis (28/01/2020), as well as for several other pharmaceuticals dating back more than 12 months ago. It was agreed that these declarations would not prevent Dr Ford from providing expert advice to the committee.
	+ 1. No further conflicts of interest were declared for this item.
	1. Part 2a – Closed session (company representatives, professional experts, members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	2. Part 2b – Closed session (external group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Thursday 4 March 2021 and will start promptly at 9:30am.